Results 1 to 10 of about 549,054 (216)

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. [PDF]

Journal of Immunotherapy for Cancer, 2017
Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete group of immune-related adverse ...
Abdallah, K., Anderson, J., Andrews, S., Arrindell, D., Ballesteros, J., Bingham, C. O., Boyer, J., Brogdon, C., Chen, D., Chonzi, D., Cotarla, I., Cunha, R., Dadu, R., Davies, M., Dawson, M., Diab, A., Dicker, Adam, Eifler, L., Ernstoff, M. S., Ferguson, A., Ferlini, C., Frankel, S., Go, W., Gochett, C., Goldberg, J., Goncalves, P., Goswami, T., Gregory, N., Gulley, J. L., Hamad, L., Hayreh, V., Helie, N., Holmes, W., Hsu, J. Y., Ibrahim, R., Kaufman, H. L., Kim, S., Lacouture, M. E., Lambotte, O., Larocca, C., LeBoeuf, N. R., Lehman, K., Lenihan, D., Ley-Acosta, S., Luke, J., McClure, J., Michelon, E., Nakamura, M., Onofrei, C., Patel, K., Piperdi, B., Puzanov, I., Rasheed, Z., Reshef, D., Riemer, J., Robert, C., Sarkeshik, M., Saylors, A., Schreiber, J., Shafer-Weaver, K., Shannon, V., Sharfman, W., Sharma, R., Sharon, E., Sherry, R., Silk, A. W., Simonson, C., Skondra, D., Suarez-Almazor, M. E., Thomas, C., Thompson, J. A., Trehu, E., Tresnan, D., Turner, M., Wang, Y., Wariabharaj, D., Waxman, I., Wiley, K., Wood, L., Zhang, L., Zheng, P.   +80 more
core   +3 more sources

Negative Immune Checkpoint Inhibitors

Pharmaceutics
Checkpoint inhibitors are a modern therapeutic approach for treating various types of cancer, metabolic diseases, and chronic infections. The main goal of this therapy is to specifically unlock the immune system, allowing it to recognize and eliminate ...
Magda Drewniak-Świtalska, Paulina Fortuna, Małgorzata Krzystek-Korpacka   +2 more
doaj   +2 more sources

Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives

Frontiers in Pharmacology, 2023
In recent years, cancer immunotherapy has made remarkable achievements. Immune checkpoint inhibitors (ICIs) have been used successfully in several types of cancer in the past decade.
Zherui Liu, Zherui Liu, Yun Zhu, Huan Xie, Zhengsheng Zou, Zhengsheng Zou, Zhengsheng Zou   +6 more
doaj   +2 more sources

Immune checkpoint inhibitors [PDF]

Journal of Experimental Medicine, 2021
Three papers by James Allison and Tasuku Honjo published in JEM between 1995 and 2000 crystallized seminal insights into the role of CTLA-4 and PD-1 in immunosuppression (Krummel and Allison. 1995. J. Exp. Med.https://doi.org/10.1084/jem.182.2.459; van Elsas et al. 1999. J. Exp. Med.https://doi.org/10.1084/jem.190.3.355; Freeman et al. 2000. J.
Kroemer, Guido, Zitvogel, Laurence
  +8 more sources

Immune checkpoint inhibitors [PDF]

Journal of Cell Biology, 2019
Hui details the cell biology underlying the action of immune checkpoint inhibitors.
Pawel Kalinski, Per Basse
  +11 more sources

Gut microbiome on immune checkpoint inhibitor therapy and consequent immune-related colitis: a review [PDF]

Intestinal Research, 2023
Immune checkpoint inhibitors have dramatically revolutionized the therapeutic landscape for patients with advanced malignancies. Recently, convincing evidence has shown meaningful influence of gut microbiome on human immune system.
Sung Wook Hwang, Min Kyu Kim, Mi-Na Kweon   +2 more
doaj   +1 more source

Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities

Frontiers in Oncology, 2022
Hepatocellular carcinoma is one of the leading causes of cancer mortality globally, and its incidence is increasing. Immune checkpoint therapy has revolutionized the treatment of hepatocellular carcinoma over the past few years.
Qingqing Xie, Pengfei Zhang, Yuanyuan Wang, Wuxuan Mei, Changchun Zeng   +4 more
doaj   +1 more source

Immune Checkpoint Inhibitors [PDF]

JAMA Oncology, 2015
Undoubtedly the discovery of immune checkpoints such as CTLA-4 and PD-1 has been crucial to the development of cancer immunotherapy. Although these molecules were originally discovered as molecules playing a role in T cell activation or apoptosis, subsequent preclinical research showed their important role in the maintenance of peripheral immune ...
John B A G, Haanen, Caroline, Robert
openaire   +3 more sources

Nano-Chemotherapy synergize with immune checkpoint inhibitor- A better option?

Frontiers in Immunology, 2022
Immune checkpoint inhibitor (ICI) is one of the most important tumor treatment methods. Although the therapeutic efficiency of immune checkpoint inhibitor mono-therapy is limited, the combination of chemotherapy plus immune checkpoint inhibitors has ...
Xinye Qian, Xinye Qian, Wang Hu, Wang Hu, Jun Yan, Jun Yan   +5 more
doaj   +1 more source

Immune Checkpoint Inhibitor Toxicities [PDF]

Mayo Clinic Proceedings, 2019
Immune checkpoint inhibitors are molecules that increase the endogenous immune response against tumors. They have revolutionized the field of oncology. Since their initial approval for the treatment of advanced melanoma, their use has expanded to the treatment of several other advanced cancers. Unfortunately, immune checkpoint inhibitors have also been
Julian A. Marin-Acevedo, Razvan M. Chirila, Roxana S. Dronca   +2 more
openaire   +2 more sources